PTO/SB/96 (12-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b) 2335.0140000/SRL/KPQ				
Applicant/Patent Owner: Heinz Von Der Kammer and Johannes Pohlner				
U.S. Nat'l Phase of Application No./Patent No./Control No.: PCT/EP2004/052353 Filed/Issue Date: I.A. Filing Date: September 29, 2004				
Entitled: Diagnostic and Therapeutic Use of a Sulfotransferase for Neurodegenerative Diseases				
Evotec NeuroSciences GmbH , a Corporation				
(Name of Assignee) (Type of Assignee: corporation, partnership, university, government agency, etc.) states that it is: 1. X the assignee of the entire right, title, and interest; or				
an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is%)				
in the patent application/patent identified above by virtue of either:				
A. X An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or a true copy of the original assignment is attached. OR				
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:				
To:				
2. From:To:				
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.				
3. From:To: _				
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.				
Additional documents in the chain of title are listed on a supplemental sheet.				
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]				
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. Mark 21 st 2006				
DR, JOHANNES POHLNER +49-40-56081273				
Printed or Typed Name Telephone Number				
MANAGING DIRECTOR				
Title				

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

DO NOT FORWARD TO ASSIGNMENT BRANCH NOT FOR RECORDATION ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: Heinz VON DER KAMMER and Johannes POHLNER, hereby sell and assign to Evotec NeuroSciences GmbH, a corporation formed under the laws of Germany, whose mailing address is Schnackenburgallee 114, Hamburg, Germany 22525 (hereafter referred to as the Assignee), their entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

- (a) in the invention(s) known as **Diagnostic and Therapeutic Use of a Sulfotransferase for Neurodegenerative Diseases** for which application(s) for patent was filed in the United States of America as the U.S. national phase of International Application No. PCT/EP2004/052353, International Filing Date: September 29, 2004, in any and all applications thereon, in any and all Letters Patent(s) therefor, and
- (b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that they have full right to convey the entire interest herein assigned, and that they have not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with CUSTOMER NUMBER 26111 the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

		executed by the und	lersigned inventors on the date
opposi	te their name.		\
Date:_	March 20th 2006	Signature of Inventor:	In va de James
			Heinz VON DER KAMMER
Date:_	March 20th 2006	Signature of Inventor:	
			Johannes POHLNER

497192_1.DOC